Dysregulated expression of both the costimulatory CD28 and inhibitory CTLA-4 molecules in PB T cells of advanced cervical cancer patients suggests systemic immunosuppression related to disease progression

Pathology and Oncology Research

Volumn 18, Issue 2, 2012, Pages 479-489

  Kosmaczewska, Agata ^a   Bocko, Dorota ^a   Ciszak, Lidia ^a   Wlodarska Polinska, Iwona ^b,c   Kornafel, Jan ^b   Szteblich, Aleksandra ^a   Masternak, Anna ^d   Frydecka, Irena ^a,b  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c International Center of Oncotherapy   (Poland)

^d Regional Hospital   (Poland)

Author keywords

CD28; Cervical cancer; CTLA 4; Progression; Systemic immunosuppression; T cell

Indexed keywords

CD28 ANTIGEN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BRACHYTHERAPY; CANCER IMMUNOLOGY; CANCER RADIOTHERAPY; CANCER STAGING; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; EX VIVO STUDY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNE DYSREGULATION; IMMUNOPATHOGENESIS; IMMUNOSTIMULATION; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER;

ADULT; AGED; ANTIGENS, CD28; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CELLS, CULTURED; CERVIX UTERI; CTLA-4 ANTIGEN; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; FOLLOW-UP STUDIES; HUMANS; IMMUNE TOLERANCE; IMMUNOSUPPRESSION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MIDDLE AGED; PROGNOSIS; T-LYMPHOCYTES; TUMOR MARKERS, BIOLOGICAL; UTERINE CERVICAL NEOPLASMS;

EID: 84863437838     PISSN: 12194956     EISSN: 15322807     Source Type: Journal    
DOI: 10.1007/s12253-011-9471-y     Document Type: Article

References (57)

1. Cheng WF, Lee CN, Su YN, Chang MC et al (2005) Induction of human papillomavirus type 16-specific immunologic responses in a normal and an human papillomavirus-infected populations. Immunology 115:136-149
2. Rellihan MA, Dooley DP, Burke TW et al (1990) Rapidly progressing cervical cancer in a patient with human immunodeficiency virus infection. Gynecol Oncol 36:435-438
3. Ahmed SM, Al-Doujaily H, Reid WMN et al (2002) The cellular response associated with cervical intraepithelial neoplasia in HIV +and HIV-subjects. Scand J Immunol 56:204-211
4. Santegoets LA, van Setyrs M, Heijmans-Antonissen C et al (2008) Reduced local immunity in HIV-related VIN: expression of chemokines and involvement of immunocompetent cells. Int J Cancer 123:616-622
5. Nasiell K, Roger V, Nasiell M (1986) Behaviour of mild cervical dysplasia during long term follow-up. Obstet Gynecol 67:665-669
6. Hilders C, Houbiers J, van Ravenswaay CH et al (1993) Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Lab Invest 69:651-659
7. Ivanson EL, Juko-Pecirep I, Gyllensten UB (2010) Interaction of immunological genes on chromosome 2q33 and IFNG in susceptibility to cervical cancer. Gynec Oncol 116:544-548
8. Pravica V, Perrey C, Stevens A et al (2000) A single nucleotide polymorphism in the first intron of the human IFN-gamma gene: absolute correlation with a polymorphic CA microsatellite marker of high IFN-gamma production. Hum Immunol 61:863-866
9. Guzman VB, Yambartsev A, Goncalves-Primo A et al (2008) New approach reveals CD28 and IFNG gene interaction in the susceptibility to cervical cancer. Hum Mol Genet 17:1838-1844
10. Kim CW, Choi SH, Chung EJ, Lee MJ et al (1999) Alteration of signal transducing molecules and phenotypical characteristics in peripheral blood lymphocytes from gastric carcinoma patients. Pathobiology 67:123-128
11. Melichar B, Nash MA, Lenzi R, et al. Expression of costimulatory molecules CD80 and CD86 and their receptors CD28, CTLA-4 on malignant ascites CD3+ tumor-infiltrating lymphocytes (TIL) from patients with ovarian and other types of peritoneal carcinomatosis. Clin Exp Immunol 119:19-27
12. Frydecka I, Kosmaczewska A, Bocko D et al (2004) Alterations of the expression of T-cell related costimulatory CD28 and down regulatory CD152 (CTLA-4) molecules n patients with B-cell chronic lymphocytic leukaemia. Br J Cancer 90:2042-2048
13. Motta M, Rassenti L, Shelvin BJ et al (2005) Increased expression of CD152 (CTLA-4) by normal T lymphocytes in untreated patients with B-cell chronic lymphocytic leukaemia. Leukemia 19:1788-1793
14. Labalette M, Leteurtre E, Thumerelle C et al (1999) Peripheral human CD8+CD28+ T lymphocytes give rise to CD28-progeny, but IL-4 prevents loss of CD28 expression. Int Immunol 11:1327-1335
15. Melichar B, Solichova D, Freedman RS (2006) Neopterin as an indicator of immune activation and prognosis in patients with gynecological malignancies. Int J Gynecol Cancer 16:240-252
16. Ligers A, Teleshova N, Masterman T et al (2001) CTLA-4 gene expression is influenced by promoter and exon 1 polymorphisms. Genes Immun 2:145-152
17. Pawlak E, Karabon L, Wlodarska-Polinska I et al (2010) Influence of CTLA-4/CD28/ICOS gene polymorphisms on the susceptibility to cervical squamous cell carcinoma and stage of differentiation in the Polish population. Hum Immunol 71:195-200
18. Su TH, Chang TY, Lee YJ, Chen CK et al (2007) CTLA-4 gene and susceptibility to human papillomavirus-16-associated cervical cell carcinoma in Taiwanese women. Carcinogenesis 28:1237-1240
19. Bortwick NJ, Lowdell M, Salmon M, Akbar AN (2000) Loss of CD28 expression on CD8+ T cells is induced by IL-2 receptor gamma chain signaling cytokines and type I IFN, and increases susceptibility to activation-inducted apoptosis. Int Immunol 12:1005-1013
20. Bryl E, Vallejo AN, Weyand CM, Goronzy JJ (2001) Downregulation of CD28 expression by TNF-alpha. J Immunol 167:3231-3238
21. Chopra V, Dinh TV, Hanningan EV (1998) Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 16:152-159
22. Gaiotti D, Chung J, Iglesias M et al (2000) Tumor necrosis factoralpha promotes human papillomavirus (HPV) E6/E7 RNA expression and cyclin-dependent kinase activity in HPV-immortalized keratinocytes by a ras-dependent pathway. Mol Carcinog 27:97-109
23. Azar KK, Tani M, Yasuda H et al (2004) Increased secretion patterns of interleukin-10 and tumor necrosis factor-alpha in cervical squamous intraepithelial lesions. Hum Pathol 35:1376-1384
24. Zijlmans HJ, Fleuren GJ, Baelde HJ et al (2007) Role of tumor-derived proinflammatory cytokines GM-CSF, TNF-alpha, and IL-12 in the migration and differentiation of antigen-presenting cells in cervical carcinoma. Cancer 109:556-565
25. Linsley P, Bradshaw J, Urnes M et al (1993) CD28 engagement by B7/BB1 induces transient down-regulation of CD28 synthesis and prolonged unresponsiveness to CD28 signalling. J Immunol 150:3161-3169
26. Higgins GD, Davy M, Roder D et al (1991) Increased age and mortality associated with cervical carcinomas negative for human papillomavirus RNA. Lancet 338:910-913
27. Ha SJ, West EE, Araki K et al (2008) Manipulating both the inhibitory and stimulatory immune system towards the success of therapeutic vaccination against chronic viral infections. Immunol Rev 223:317-333
28. Nakamoto N, Cho H, Shaked A et al (2009) Synergistic reversal of intrahepatic HCV-specific CD8 T cell exhaustion by combined PD-1/CTLA-4 blockade. PLoS Pathogens 5:e1000313
29. Brittenden J, Heys SD, Ross J, Eremin O (1996) Natural killer cells and cancer. Cancer 77:1226-1243
30. Cosiski-Marana HR, Santana da Silva J, Moreira de Andrade J (2000) NK cell activity in the presence of IL-12 is a prognostic assay to neoadjuvant chemotherapy in cervical cancer. Gynecol Oncol 78:318-323
31. Kern DE, Klarnet JP, Jensen MCV, Greenberg PD (1986) Requirement for recognition of class II and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol 136:4303-4310
32. Kosmaczewska A, Frydecka I, Bocko D et al (2002) Correlation of blood lymphocyte CTLA-4 (CD152) induction in Hodgkin's disease with proliferative activity, interleukin 2 and interferon gamma production. Br J Haematol 118:202-209
33. Carreno BM, Bennett F, Chau TA et al (2000) CTLA-4 (CD152) can inhibit T cell activation by two different mechanisms depending on its level of cell surface expression. J Immunol 165:1352-1356
34. Scotto L, Naiyer AJ, Galluzzo S et al (2004) Overlap between molecular markers expressed by naturally occurring CD4+CD25+regulatory T cells and CD8+CD28- T suppressor cells. Hum Immunol 65:1297-1306
35. Sansom DM, Walker LS (2006) The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 212:131-148
36. Karagoz B, Bilgi O, Gumus M et al (2010) CD8+CD28- cells and CD4+CD25+ regulatory T cells in the peripheral blood of advanced stage lung cancer patients. Med Oncol 27:29-33
37. Mahic M, Henjum K, Yaqub S et al (2008) Generation of highly suppressive adaptive CD8(+)CD25(+)FOXP3(+) regulatory T cells by continuous antigen stimulation. Eur J Immunol 38:640-646
38. Zheng SG, Wang JH, Stohl W et al (2006) TGF-beta requires CTLA-4 early after T cell activation to induce FoxP3 and generate adaptive CD4+CD25+ regulatory cells. J Immunol 176:3321-3329
39. Takahashi T, Tagami T, Yamazaki S et al (2000) Immunologic self-tolerance maintained by CD25+CD4+ regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 192:303-309
40. Visser J, Nijman HW, Hoogenboom B-N et al (2007) Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 150:199-209
41. June CH, Ledbetter JA, Linsley PS, Thompson CB (1990) Role of CD28 receptor in T-cell activation. Immunol Today 11:211-216
42. Filaci G, Fravega M, Negrini S et al (2004) Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function. Hum Immunol 65:142-156
43. Chopra V, Dinh TV, Hannigan EV (1998) Circulating serum levels of cytokines and angiogenic factors in patients with cervical cancer. Cancer Invest 16:152-159
44. Diaz-Benitez CE, Navarro-Fuentes KR, Flores-Sosa JA et al (2009) CD3zeta expression and T cell proliferation are inhibited by TGF-beta1 and IL-10 in cervical cancer patients. J Clin Immunol 29:32-544
45. Mahic M, Yaqub S, Bryn T et al (2008) Differentiation of naïve CD4+ T cells into CD4+CD25+FOXP3+ regulatory T cells by continuous antigen stimulation. J Leukoc Biol 83:1111-1117
46. Clerici M, Merola M, Ferrario E et al (1997) Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 89:245-250
47. Tartour E, Gey A, Sastre-Garau E et al (1998) Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas. J Natl Cancer Inst 90:287-294
48. Santin AD, Ravaggi A, Bellone S et al (2001) Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Gynecol Oncol 81:424-432
49. Kusuda T, Shigemasa K, Arihiro K et al (2005) Relative expression levels of Th1 and Th2 cytokine mRNA are independent prognostic factors in patients with ovarian cancer. Oncol Rep 13:1153-1158
50. Ubukata H, Motohashi G, Tabuchi T et al (2010) Evaluations of interferon-gamma/interleukin-4 ratio and neutrophil/lymphocyte ratio as prognostic indicators in gastric cancer patients. J Surg Oncol 102:742-747
51. Teschendorff AE, Gomez S, Arenas A et al (2010) Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules. BMC Cancer 10:604
52. Tosolini M, Kirilovsky A, Mlecnik B et al (2011) Clinical impact of different classes of infiltrating T cytotoxic and helper cells (Th1, Th2, Treg, and Th17) in patients with colorectal cancer. Cancer Res 71:1263-1271
53. De Monte L, Reni M, Tassi E et al (2011) Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer. J Exp Med 208:469-478
54. Eylar EH, Lefranc C, Baez I et al (2001) Enhanced interferongamma by CD8+CD28- lymphocytes from HIV+patients. J Clin Immunol 21:135-144
55. Wang YM, Alexander SI (2009) CD8 regulatory T cells: what's old is now new? Immunol Cell Biol 87:192-193
56. Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420:860-867
57. Ito N, Suzuki Y, Taniguchi Y et al (2005) Prognostic significance of T helper 1 and 2 and T cytotoxic 1 and 2 cells in patients with non-small cell lung cancer. Anticancer Res 25:2027-2032